| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8454996 | OREXO US INC | Pharmaceutical composition for the treatment of acute disorders |
Sep, 2019
(4 years ago) | |
| US8658198 | OREXO US INC | Non-abusable pharmaceutical composition comprising opioids |
Dec, 2027
(3 years from now) | |
| US8470361 | OREXO US INC | Non-abusable pharmaceutical composition comprising opioids |
May, 2030
(6 years from now) | |
| US10946010 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
| US9259421 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
| US9439900 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
| US8940330 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
| US11020388 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
| US11433066 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
| US11020387 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
| US10874661 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(8 years from now) | |
Zubsolv is owned by Orexo Us Inc.
Zubsolv contains Buprenorphine Hydrochloride; Naloxone Hydrochloride.
Zubsolv has a total of 11 drug patents out of which 1 drug patent has expired.
Expired drug patents of Zubsolv are:
- US8454996
Zubsolv was authorised for market use on 04 October, 2016.
Zubsolv is available in tablet;sublingual dosage forms.
Zubsolv can be used as sublingual administration of a pharmaceutical composition comprising buprenorphine, sublingual or buccal administration of a pharmaceutical composition comprising buprenorphine and naloxone, sublingual administration of a pharmaceutical composition comprising buprenorphine and naloxone, use of zubsolv for treatment of opioid dependence.
The generics of Zubsolv are possible to be released after 18 September, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-713) | Aug 10, 2018 |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 October, 2016
Treatment: Sublingual administration of a pharmaceutical composition comprising buprenorphine; Sublingual or buccal administration of a pharmaceutical composition comprising buprenorphine and naloxone; Sublingua...
Dosage: TABLET;SUBLINGUAL
ZUBSOLV family patents
